MindBio Therapeutics Appoints Haywood Securities to Provide Strategic Investment Advice

VANCOUVER, BC / ACCESSWIRE / August 1, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the “Company” or “MindBio”), a leading biopharmaceutical company in the development of psychiatric drugs, is pleased to announce that it has appointed Haywood Securities Inc. (“Hay wood“) to act as a strategic advisor to the company in support of its short-term objectives.

Haywood’s services will focus on supporting the company in securing potential strategic investments and transactions with strategic partners.

The terms of the agreement provide for compensation by payment in Warrants, with a maximum of 7,500,000 Warrants to be issued in payment for a minimum commitment of 6 months. Customary success fees are also payable upon successful completion of a transaction.

MindBio has achieved a significant milestone with multiple ongoing Phase 2B clinical trials receiving government and regulatory approvals for home use and ingestion of a psychedelic drug by trial patients on their own and in the community. MindBio’s lead drug candidate MB22001 has shown promising results in Phase 1 and Phase 2A Depression trials, demonstrating excellent safety and adherence, substantial effects on mood, improvements in sleep, and significantly reduced depressive symptoms.

MindBio’s thesis is that microdosing psychedelic drugs is a globally scalable, effective, and affordable way to treat patients with mental health conditions without the side effects of antidepressants. The company currently has two Phase 2B clinical trials underway (a depression trial and a cancer trial) and those trials are set to run well into 2025.

The company also recently conducted a third Phase 2B study in PMS (premenstrual syndrome) and PMDD (premenstrual dysphoric disorder), for which home administration has been approved.

Justin Hanka, Chief Executive Officer of MindBio, commented, “We are pleased to appoint Haywood to advise and lead our strategic investment initiatives as we prepare the company for late-stage clinical trials.”

We invite you to join us in working toward a better future for mental health care.

Get our latest updates here: https://www.mindbiotherapeutics.com/get-updates

Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true

Follow CEO Justin Hanka on LinkedIn: https://www.linkedin.com/in/justinhanka/

For further information, please contact:

Justin Hanka, CEO
61 433140886
[email protected]

Questions from the media
Kristina Spionjak
[email protected]

About MindBio Therapeutics

MindBio is a leading biotechnology/biopharmaceutical company focused on creating new and emerging treatments for mental health conditions and is conducting the world’s first clinical trial of home microdosing (MB22001). MB22001 is MindBio’s lead drug candidate, a proprietary titratable form of lysergic acid diethylamide (LSD) designed for home microdosing. MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multidisciplinary treatment development platform and is involved in the development of psychedelic medicines and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy participants and has completed a Phase 2a clinical trial in patients with Major Depressive Disorder, both trials reporting positive topline data. Currently, two Phase 2B trials are underway, one in cancer patients experiencing existential distress and another in patients with major depressive disorder. The company has also been approved for multiple Phase 1/Phase 2B trials in women’s health. MindBio invests in research that forms the basis for the development of novel and clinically proven treatments, including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.

About Haywood

Founded in 1981, Haywood is a 100 percent employee-owned investment dealer with over 340 employees across its Canadian offices in Vancouver, Calgary and Toronto. Haywood Securities Inc. is a member of the Toronto Stock Exchange, the TSX Venture Exchange, the Montreal Exchange (MEX), the Canadian Securities Exchange (CSE), the Canadian Investor Protection Fund (CIPF) and the Investment Industry Regulatory Organization of Canada (IIROC). In addition, Haywood Securities (USA) Inc., a wholly owned subsidiary, is a broker-dealer registered to transact securities in the United States and is a member of the Financial Industry Regulatory Authority (FINRA).

Cautionary Note Regarding Forward-Looking Statements:

The press release contains “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: “anticipate”, “intend”, “plan”, “budget”, “believe”, “project”, “estimate”, “expect”, “scheduled”, “predict”, “strategy”, “future”, “likely”, “may”, “are”, “would”, “should”, “will” and similar references to future periods or the negative or comparable terminology, as well as terms customarily used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are made. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

In addition, there are known and unknown risk factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Accordingly, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others: general economic, market and business conditions in Canada and Australia; market volatility; unanticipated delays in timelines for any of the transactions or events described in this press release. All forward-looking information is qualified in its entirety by this cautionary statement.

The Company disclaims any obligation to revise or update any such forward-looking statement or to release publicly the results of any revisions to the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE: MindBio Therapeutics

View the original press release at accesswire.com